RxDoctor Payments Data

Stelian Marinescu, MD

Internal Medicine · Dearborn, MINPI 1235109513

Payments from drug & device makers

$5,574in general payments, 2019–2025

Across 224 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Johnson & Johnson$843
  • Boston Scientific$500
  • E.r. Squibb & Sons, L.L.C.$462
  • AstraZeneca$255
  • Novartis$244
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$1,27623%
  • Food & beverage$4,28077%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,574 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$249,008
Medicare patients
446
Services billed
2,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$468,476
EntrestoSacubitril/Valsartan144$192,684
JardianceEmpagliflozin153$163,564
BrilintaTicagrelor152$146,437
XareltoRivaroxaban118$121,686
Repatha SureclickEvolocumab61$60,541
MultaqDronedarone Hcl28$46,458
FarxigaDapagliflozin Propanediol33$38,330
Isosorbide Dinitrate285$19,669
ClopidogrelClopidogrel Bisulfate493$9,140
Atorvastatin Calcium534$7,948
Carvedilol560$6,463
Metoprolol Succinate196$3,808
Ezetimibe136$2,975
Losartan Potassium208$2,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$468,476374 claims
NovartisEntresto$244$192,684144 claims
AstraZenecaBrilinta, Farxiga$255$184,767185 claims
Boehringer IngelheimJardiance$100$163,564153 claims
Johnson & JohnsonXarelto$843$121,686118 claims
Sanofi-aventis U.S. LLCMultaq$171$46,45828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →